Evidence grade CTissue & gut repair

BPC-157

Also known as Body Protection Compound 157, PL 14736

A synthetic peptide fragment studied for tendon, muscle, and gut healing — popular in recovery circles, though human evidence remains limited.

Evidence grade C · 11 citations · Last reviewed October 2026

Regulatory status
Not FDA-approved. In a draft, non-binding policy from October 28, 2026, HHS says it does not intend to bring enforcement action against 503A pharmacies and physicians that compound BPC-157 acetate for a patient-specific prescription, provided ten stated conditions are met, while FDA rulemaking settles whether it joins the 503A bulks list. That is enforcement discretion, not approval. Human data remain largely preclinical.
Common routes
Subcutaneous · intramuscular · oral · topical (the routes the HHS policy covers)

BPC-157 dosage: what the FDA has actually published →

BPC-157: the quick answer

What is BPC-157?
A synthetic peptide of 15 amino acids, built on a sequence first found in human gastric juice, and sold for tendon, gut and injury recovery.
How strong is the evidence?
Mostly rat and cell studies. Three small uncontrolled human studies (30 people in total) exist, and a 2026 systematic review rated their certainty very low. No controlled human trial has been completed.
US status (as of October 2026)
Not FDA-approved. Under a draft, non-binding policy, HHS says it does not intend to bring enforcement action against 503A compounding of BPC-157 acetate when ten conditions are met, for subcutaneous or intramuscular injection, oral, or topical use. Research-chemical vials are outside the policy. Banned in sport under WADA S0.

Overview

BPC-157 (Body Protection Compound 157) is a synthetic peptide of 15 amino acids, built on a stretch of sequence first isolated from human gastric juice. It was identified in the 1990s by researchers studying the stomach's mucosal-protective mechanisms [1]. The peptide attracted early interest because of its apparent stability in gastric acid and its effects on healing in rodent models. Today it is widely discussed in recovery, biohacking, and sports communities for supposed tendon, gut, and soft-tissue repair properties.

The scientific reality is that the evidence base for BPC-157 is almost entirely preclinical: studies in cells and rats, not humans. No peer-reviewed randomized controlled trial has been completed in human subjects for any indication. Its regulatory position changed on October 28, 2026, when HHS announced a draft, non-binding policy saying it will not take enforcement action against licensed 503A pharmacies and physicians that compound BPC-157 acetate under ten conditions, by subcutaneous or intramuscular injection, orally, or topically [8]. That makes a prescribed, pharmacy-made product possible again. It is not FDA approval, and much of what is sold online is still unregulated research chemical.

This page summarizes what the published literature actually shows, with every claim grounded in verified, peer-reviewed sources. Claims that appear only in animal research are explicitly labeled as preclinical. Readers should treat enthusiasm from online recovery communities as anecdote, not evidence.

Regulatory status

FDA has not approved BPC-157 for any use. What changed on October 28, 2026 is enforcement, not approval: HHS released a draft, interim enforcement-discretion policy (not final, binding on neither HHS nor the public, and its comment period closed on November 13, 2026). FDA is still working out through rulemaking whether BPC-157 should go on the 503A bulk drug substances list. In the meantime, HHS says it does not intend to bring enforcement action against BPC-157 acetate compounding when all ten conditions are satisfied and the compounder is a State-licensed pharmacy, a licensed physician, or a Federal facility [8]. The same document points out that compounded drugs carry no FDA approval and get no FDA review for safety, effectiveness, or quality.

Route limits: the policy covers BPC-157 acetate in subcutaneous, intramuscular, oral, and topical dosage forms [8]. Intravenous BPC-157 is outside it. An oral product also needs paperwork behind it: the compounder should hold records showing that its own oral formulation achieves adequate bioavailability in people.

Among the remaining conditions: a prescription written for one patient; bulk peptide made by an FDA-registered manufacturer and backed by a certificate of analysis that tests identity, purity and potency and sets limits for endotoxin, heavy metals, microbes and impurities; only one active ingredient per product, so the BPC-157 and TB-500 blends sold widely online do not qualify; a label carrying the policy's sentence "This is a compounded drug product. Not for resale."; no co-packaged device other than a 510(k)-cleared syringe; and reports to FDA MedWatch and the states whenever a serious adverse event or quality defect occurs [8]. HHS has kept the option of reconsidering the whole arrangement should safety or quality concerns surface.

History: BPC-157 (free base) and BPC-157 acetate were in FDA's Category 2 from September 2023 until April 22, 2026. CDER recommended against listing them, and the Pharmacy Compounding Advisory Committee voted in favor of inclusion [8]. HHS gave three reasons for going ahead: documented historical use and human studies; a certificate of analysis for a specific lot, issued by an FDA-registered facility, that supplied the identity, impurity, endotoxin, microbial and residual-solvent data CDER had said were missing; and the safeguards written into the policy itself [8].

Comparing providers? See our full ranking of BPC-157 providers, scored, compared, and updated monthly.View ranking →

Where to get BPC-157

Every telehealth provider we track that offers BPC-157. Partners we work with are shown first.

7.7/ 10
Partner

Live Vital

Best for: low-cost, physician-led compounded GLP-1 with peptide and hormone options

★★★★☆3.9/5

Editorial score · methodology

$130/mosemaglutide
after intro offer
$239/motirzepatide
after intro offer
CompoundedSemaglutideTirzepatideBPC-157CJC-1295 / Ipamorelin
Get StartedRead full Live Vital review →
6.9/ 10
Partner

YourEra

Best for: flat month-to-month pricing on compounded GLP-1s at every dose

★★★★☆3.5/5

Editorial score · methodology

$89/mosemaglutide
$129/motirzepatide
CompoundedSemaglutideTirzepatideBPC-157KPVLegitScript Verified
Get StartedRead full YourEra review →
7.9/ 10

Pepti

Best for: a low all-in starter price on compounded GLP-1s, with every dose price published up front

★★★★☆4/5

Editorial score · methodology

$99/4 wkssemaglutide
billed per 4 weeks
$159/4 wkstirzepatide
billed per 4 weeks
CompoundedSemaglutideTirzepatideBPC-157Epitalon
Get StartedRead full Pepti review →
7.5/ 10

Ivologist

Best for: patients who want a fixed three-month prepay instead of an open-ended plan, or a simple monthly plan

★★★★☆3.8/5

Editorial score · methodology

$199/mosemaglutide
see plan details
$299/motirzepatide
see plan details
CompoundedSemaglutideTirzepatideBPC-157NAD+LegitScript Verified
Get StartedRead full Ivologist review →
7.5/ 10

Ivy Rx

Best for: compounded GLP-1 at one price for every dose, with a microdose option and no lab work

★★★★☆3.8/5

Editorial score · methodology

$175/mosemaglutide
starting dose
$275/motirzepatide
starting dose
CompoundedSemaglutideTirzepatideBPC-157GlutathioneLegitScript Verified
Get StartedRead full Ivy Rx review →
7.4/ 10

OurView Health

Best for: low, flat compounded GLP-1 pricing at any dose, with no membership fee

★★★★☆3.7/5

Editorial score · methodology

$109/mosemaglutide
$129/motirzepatide
CompoundedSemaglutideTirzepatideBPC-157KPVLegitScript Verified
Get StartedRead full OurView Health review →
7.4/ 10

Ryze Rx

Best for: compounded GLP-1s plus a broad TRT and peptide menu on one platform

★★★★☆3.7/5

Editorial score · methodology

$119/mosemaglutide
starting dose
$199/motirzepatide
starting dose
CompoundedSemaglutideTirzepatideBPC-157Epitalon
Get StartedRead full Ryze Rx review →
7.3/ 10

HuHealth

Best for: choosing your compounding pharmacy, or brand Zepbound and Wegovy at the maker's price plus a $59 care plan

★★★★☆3.7/5

Editorial score · methodology

$179/mosemaglutide
$249/motirzepatide
CompoundedSemaglutideTirzepatideOrforglipronBPC-157LegitScript Verified
Get StartedRead full HuHealth review →
7.2/ 10

Enhanced

Best for: prepaying for low-cost compounded GLP-1s with peptides available from one brand

★★★★☆3.6/5

Editorial score · methodology

$129/mosemaglutide
$169/motirzepatide
CompoundedSemaglutideTirzepatideBPC-157Epitalon
Get StartedRead full Enhanced review →
7.1/ 10

RxPepsDirect

Best for: Lowest per-vial GLP-1 cost: sema $25, tirz $45, $39 telehealth Rx, 28 states

★★★★☆3.6/5

Editorial score · methodology

$49/vialsemaglutide
$75/vialtirzepatide
CompoundedSemaglutideTirzepatideBPC-157CJC-1295 / Ipamorelin
Get StartedRead full RxPepsDirect review →
7.0/ 10

FormBlends

Best for: transparent, flat-priced compounded semaglutide or tirzepatide with no membership fee

★★★★☆3.5/5

Editorial score · methodology

$190/4 wkssemaglutide
billed per 4 weeks
$239/4 wkstirzepatide
billed per 4 weeks
CompoundedSemaglutideTirzepatideBPC-157Epitalon
Get StartedRead full FormBlends review →
7.0/ 10

Rewinding RX

Best for: longevity-framed GLP-1 with MD-only review and flat any-dose pricing

★★★★☆3.5/5

Editorial score · methodology

$139/mosemaglutide
$189/motirzepatide
SemaglutideTirzepatideBPC-157MOTS-cLegitScript Verified
Get StartedRead full Rewinding RX review →

Also offered by 5 more providers we track

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

What does BPC-157 do? Claims vs evidence

Each row is a claim as it is commonly marketed, the strongest kind of evidence behind it, and what that evidence found. Numbers in brackets point to the sources at the end of this page.

BPC-157 claims compared with the published evidence
Heals tendons, ligaments and muscleAnimal studiesRat studies from the Zagreb group that developed BPC-157 report faster tendon, ligament, muscle and junction healing, given by injection, by mouth or as a cream. No controlled human trial has tested it.Sources:[5]
Repairs the gut lining and leaky gutAnimal studiesReviews of rodent and cell work report that BPC-157 protects the stomach and intestinal lining against alcohol, NSAIDs and other irritants. The leaky-gut case is drawn from that work; no human gut study exists.Sources:[2][3]
Grows new blood vessels to speed healingAnimal studiesReviews of the animal research describe effects on blood vessel growth (angiogenesis) and the nitric oxide system. These are mechanism findings in animals, not a measured effect in people.Sources:[4]
Relieves knee and joint painHuman studiesOne retrospective study of 16 people given knee injections reported symptom improvement in most of them. It had no control group, and the 2026 systematic review rated all human BPC-157 evidence very low certainty.Sources:[9]
Eases interstitial cystitis (bladder pain)Human studiesA retrospective pilot of 12 people given BPC-157 into the bladder reported improvement in most. No control group; very low certainty.Sources:[9]
Proven safe in humansHuman studiesAcross the three human studies (30 people, including a two-person IV pilot of 10 mg and 20 mg), no treatment-related adverse events were reported. That is far too few people, followed too briefly, to establish safety.Sources:[9][10]

Evidence levels, strongest first: FDA-approved use, human studies (of any size or design), animal studies, cell studies only, and no direct evidence (nothing tests the claim for this compound).

How it works

In preclinical models, BPC-157 is proposed to act through modulation of the nitric oxide (NO) system and promotion of angiogenesis, meaning new blood vessel formation within damaged tissue [4]. It appears to interact with vascular endothelial growth factor (VEGF) pathways and to influence nitric oxide synthase activity, which may partly explain the wound-healing signals seen in rats. In the gastrointestinal tract, BPC-157 has been studied for its ability to protect the intestinal mucosa against injury from NSAIDs and other stressors by stabilizing mucosal barrier integrity and reducing local inflammation [2] [3].

Musculoskeletal repair is the use most heavily marketed, and here preclinical data suggest BPC-157 may speed fibroblast proliferation and tendon-to-bone remodeling after injury in rats [5]. Exactly which molecular pathway is responsible remains incompletely characterized, and the gap between rodent pharmacology and human therapeutic effect is large and unvalidated [6].

What the evidence says

The BPC-157 evidence base is overwhelmingly preclinical. The published literature originates largely from a single research group at the University of Zagreb led by Predrag Sikiric, which has conducted extensive rat-model studies over three decades covering gastric mucosal protection [1] [2], tendon and ligament healing [5], and vascular biology [4]. These studies are internally consistent and mechanistically suggestive, but they are animal data, not human clinical evidence.

A 2026 translational review in Pharmaceutics by Mateescu et al. explicitly characterizes BPC-157 as an 'investigational peptide therapeutic' and identifies the complete absence of completed Phase I or Phase II human clinical trials as a fundamental barrier to clinical translation [6]. The review catalogs formulation challenges and biopharmaceutical uncertainties that further complicate the path to human studies. In plain terms: no human trial has been completed and published.

An independent 2026 review in Sports Medicine by Mendias and Awan evaluated the evidence for approved and unapproved peptide therapies in musculoskeletal injury and athletic performance. BPC-157 was among the unapproved peptides reviewed, and the authors concluded that the human clinical evidence is insufficient to support recommendations for its use in patients or athletes [7].

A 2026 systematic review searched for every human study of BPC-157 through June 1, 2026 and found three, with 30 participants in total: a retrospective study of knee injections (16 people), a retrospective pilot of bladder instillation for interstitial cystitis (12), and an intravenous safety pilot (2). All reported symptom improvement in most participants without treatment-related adverse events, but the reviewers found the methods weak and graded the certainty of the whole body of evidence as very low [9]. None is a controlled trial.

Evidence grade: C (preclinical only). Online claims of BPC-157's effectiveness for tendon repair, gut healing, or recovery in humans are extrapolations from animal data. The failure to conduct or complete human trials over three-plus decades of preclinical work is itself informative about the translational challenges involved.

Typical dosing

No human dose has been established, because no controlled human trial has been completed. The only human dosing in the published literature comes from the three small uncontrolled studies the 2026 systematic review rated very low certainty [9]. For context only, one of them, an IRB-approved safety pilot in two adults at a private clinic, infused 10 mg of BPC-157 intravenously on day one and 20 mg on day two and reported no side effects [10]. That is a two-person safety protocol by a route the HHS policy does not cover, not a dose recommendation. The per-day microgram figures repeated on vendor sites and forums have no published human basis, so we do not repeat them.

Oral formulations are widely available as research chemicals, and we weigh capsules against injections in oral BPC-157 versus injection. Proponents argue that BPC-157 retains stability in gastric acid, which may support some oral bioavailability, though absorption data in humans do not exist. That gap matters under the HHS policy, which expects a compounder making an oral BPC-157 product to document adequate oral bioavailability in humans for that specific formulation [8]. If a clinician prescribes compounded BPC-157, the dose and schedule are their decision; the policy sets routes, not doses.

Safety & side effects

The long-term safety profile of BPC-157 in humans is unknown; our review of BPC-157 side effects and safety goes through each of the few human reports. Preclinical rat studies have not identified frank organ toxicity at doses studied, but rodent safety data are not a reliable surrogate for human safety for complex peptides. The 2026 Mendias and Awan review noted that unapproved peptides including BPC-157 carry inherent risks from unregulated manufacturing, unknown purity, and the complete absence of pharmacovigilance data [7]. Products purchased as research chemicals online may contain incorrect doses, impurities, or different peptide sequences than labeled.

Regulatory context: BPC-157 is not FDA-approved for any human medical indication. The Pharmacy Compounding Advisory Committee voted to put it on the 503A bulks list even though FDA's drug center advised against doing so. Then, in a draft policy dated October 28, 2026, HHS stated that it does not intend to bring enforcement action against 503A compounding that meets its conditions while FDA reaches a decision [8]. A product compounded under those conditions has documented identity and purity, which research-chemical vials do not. Neither route of supply changes the absence of controlled human safety data. For athletes, WADA's 2026 Prohibited List names BPC-157 under S0, non-approved substances, prohibited at all times [11].

Frequently asked questions

Is BPC-157 legal in the United States?

BPC-157 is not a scheduled controlled substance, and it is not FDA-approved for human use. In a draft policy from October 28, 2026, HHS says it does not intend to bring enforcement action against licensed 503A pharmacies and physicians that compound BPC-157 acetate for an individual patient (by injection, by mouth, or on the skin) under ten conditions. Research-chemical BPC-157 sold online as not for human consumption is outside that policy.

Does BPC-157 work in humans?

There is no completed, peer-reviewed randomized controlled trial establishing that BPC-157 is effective in humans for any purpose. All evidence of efficacy comes from rat and cell-culture studies. The absence of human trial data after more than 30 years of preclinical research is notable. Personal testimonials and online anecdotes cannot distinguish the peptide's effect from placebo, rest, or other variables.

What does BPC-157 do?

In rats, BPC-157 has been linked with faster tendon and ligament healing, protection of the gut lining from NSAID damage, and growth of new blood vessels in injured tissue [5] [2] [4]. In people, the evidence is three small uncontrolled studies with 30 participants in total, rated very low certainty [9]. No controlled human trial has shown that it treats any condition, and it has no approved medical use.

Is BPC-157 safe?

Nobody knows yet. The three published human studies, 30 people in total, reported no treatment-related adverse events, but a 2026 systematic review graded that evidence very low certainty [9], and long-term safety has never been studied. Research-chemical vials add a separate risk, because their identity, purity and dose are unverified [7]. A product compounded under the HHS policy must come with a lot-level certificate of analysis [8], which addresses quality, not the missing safety data.

BPC-157 side effects: what has been reported?

Very little, because so few people have been studied. The three human studies reported no treatment-related adverse events [9]. In the two-person intravenous pilot, 10 mg and 20 mg infusions caused no reported side effects and no measurable change in heart, liver, kidney, thyroid or blood glucose markers [10]. Groups that small cannot rule out uncommon side effects, and no study has followed people taking BPC-157 for months or years.

Can I get BPC-157 from a compounding pharmacy?

Yes, with a prescription. In a draft policy dated October 28, 2026, HHS says it does not intend to bring enforcement action against 503A compounders of BPC-157 acetate that meet its conditions. The policy is not final and is not binding. Its conditions include a product with BPC-157 alone, from a registered manufacturer with a certificate of analysis, given subcutaneously, intramuscularly, orally, or topically. BPC-157 was in FDA's Category 2 from September 2023 until April 22, 2026. Vials and capsules sold on peptide vendor websites remain unregulated research chemicals.

Is BPC-157 banned in sports?

Yes. BPC-157 appears by name on WADA's 2026 Prohibited List under S0, non-approved substances, a category banned year-round whether or not an athlete is competing. A prescription for a compounded product under the HHS policy does not change its status in sport.

Why do so many people claim BPC-157 worked for them?

Anecdotal reports are not scientific evidence. Injury recovery improves naturally over time, and self-reported improvement while taking any substance is subject to placebo effect, regression to the mean, and the fact that people typically rest more when injured. Without a control group and blinding, individual accounts cannot establish causation. The only way to know if a compound works is through controlled clinical trials, and none have been completed for BPC-157.

Sources

  1. [1] Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris (1993). PMID 8298609
  2. [2] Sikiric P, Seiwerth S, Rucman R, et al. Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution? Curr Pharm Des (2017). PMID 28228068
  3. [3] Park JM, Lee HJ, Sikiric P, et al. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des (2020). PMID 32445447
  4. [4] Sikiric P, Seiwerth S, Skrtic A, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals (Basel) (2025). PMID 40573323
  5. [5] Matek D, Matek I, Japjec M, et al. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review. Pharmaceuticals (Basel) (2026). PMID 41754849
  6. [6] Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics (2026). PMID 42198317
  7. [7] Mendias CL, Awan TM Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med (2026). PMID 41966639
  8. [8] US Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A: list; Appendix B: identities, routes, and justifications). HHS (2026). Source
  9. [9] Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg (2026). PMID 42885452
  10. [10] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med (2025). PMID 40131143
  11. [11] World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances; S2.3 Growth factors and growth factor modulators; S4.4 Metabolic modulators). WADA (2026). Source

Further reading

Related peptides

Browse the full peptide directory, see what GLP-1s treat by condition, or compare the best GLP-1 providers.

Educational information only — not medical advice.